ABI 793
Alternative Names: Anti-CD154 monoclonal antibody - NovartisLatest Information Update: 22 Jun 2007
At a glance
- Originator Novartis
- Class Monoclonal antibodies
- Mechanism of Action CD40 ligand inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Transplant rejection; Xenotransplant rejection
Most Recent Events
- 22 Jun 2007 Discontinued - Preclinical for Transplant rejection in Switzerland (unspecified route)
- 22 Jun 2007 Discontinued - Preclinical for Transplant rejection in USA (unspecified route)
- 22 Jun 2007 Discontinued - Preclinical for Xenotransplant rejection in Switzerland (unspecified route)